Observational study / 2012
In women operated on for early breast cancer, serum enterolactone levels ≥ 10 nmol/l were linked to reduced all-cause and breast cancer-specific mortality.
Researchers measured serum enterolactone levels in 300 patients operated on for early breast cancer to evaluate mortality risk over a median follow-up of 23 years (range 0.6-26.1). During follow-up, 180 patients died, including 112 from breast cancer-related events. Enterolactone levels ≥ 10 nmol/l were significantly associated with lower risks of both all-cause and breast cancer-specific mortality. The difference in mortality hazards appeared to decrease and lose significance after the first 10 years, though competing risk analysis indicated breast cancer-related mortality risk remained constantly lower in patients with higher enterolactone levels.
Shows an association, not proof of cause and effect.
- Study type
- Retrospective cohort study
- Who was studied
- 300 women operated on for early breast cancer
- What was measured
- All-cause mortality and breast cancer-specific mortality
THE PAPER
Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study.
Guglielmini P, Rubagotti A, Boccardo F. Breast Cancer Res Treat, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.